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Abstract The controversial topic of the early exposure to
mercury is regarding ethylmercury, which is present in the
thimerosal-containing vaccines (TCVs). The objective of this
study was to determine the relationship between the early
exposure to TCVs and cognitive development in children
during the first 9 years of life. The cohort included 318
children vaccinated in an early period (neonatal and up to
6 months) against hepatitis B and diphtheria-tetanus-pertussis
(DTP) using formulation with or without thimerosal. The
children’s development was assessed using the Fagan test
(6th month of life), the Bayley Scales of Infant Development
(BSID)-II (12th–36th month), the Raven test (5th, 8th year),
and the Wechsler Intelligence Scale for Children (WISC-R)
(6th, 7th, 9th year). Results were determined by multivariable
linear and logistic regression, adjusted to potential con-
founders. Children exposed and not exposed to TCVs in the
neonatal period had similar outcomes of cognitive-
developmental tests; only the results of BSID-II at the 36th
month and WISC-R at the 9th year were significantly higher
for those exposed to TCVs. Developmental test results in
children exposed to TCVs up to the 6th month of life also
did not depend on thimerosal dose.
Conclusion: TCV administration in early infancy did not
affect children’s cognitive development.
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Abbreviations
BSID-II Bayley Scales of Infant Development-Second
Edition
DTP Diphtheria-tetanus-pertussis
FTII Fagan Test of Infant Intelligence
ETS Environmental tobacco smoke
MDI Mental Development Index of BSID-II
TONI-3 Test of Nonverbal Intelligence, Third Edition
TCVs Thimerosal-containing vaccines
WISC-R Wechsler Intelligence Scale for
Children-Revised
Introduction
High doses of mercuric compounds are nephrotoxic and neu-
rotoxic. Cumulative exposure to an organic mercury-
containing compound, methylmercury, can also produce neu-
rologic and renal damage. It has a long half-life and can cross
the blood-brain barrier, where it accumulates and is converted
to inorganic mercury [16]. Ethylmercury, a related organic
mercury compound, is a constituent of thimerosal, an antibac-
terial agent used in certain non-live vaccines. Ethylmercury
has a much shorter half-life than methylmercury, being rapidly
excreted via stools after parenteral administration, but its
influence on children’s health has not been determined yet
[18, 19]. Nevertheless, the guidelines to limit cumulative
methylmercury exposure have been translated to
ethylmercury.
The discussion on the safety of thimerosal-containing
vaccines (TCVs) started in 1999 (Joint Statement issued
by the American Academy of Pediatrics and the US
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Public Health Service in July 1999) [11]. It was
suspected that ethylmercury contained in the vaccines
had a harmful effect on children’s neurodevelopment. In
fact, the low-dose human exposure to ethylmercury has
not been assessed sufficiently, although it is assumed to
have a similar effect as the exposure to methylmercury
that demonstrated harmful consequences [6, 7, 9]. Since
2004, no vaccines recommended and routinely used in
the USA and the European Union to protect preschool
children have contained thimerosal [4, 20]. Nevertheless,
most countries continue to use TCVs in their childhood
immunization schedules.
The objective of this study was to determine the relation-
ship between the early exposure to TCVs and cognitive de-
velopment in children up to the 9th year of life.
Material and methods
This is a prospective cohort study, combining environmental
monitoring and molecular approaches with comprehensive
neurodevelopment assessments. In the analysis, we used data
on the vulnerability of a fetus and child to environmental
factors, coming from an earlier established birth cohort of
children in Krakow, being part of an ongoing, collaborative
study together with Columbia University in New York. The
study has received the approval of the Jagiellonian University
Ethical Committee (Krakow, Poland).
The enrolment (November 3, 2000–August 22, 2003) in-
cluded only non-smoking women, aged 18–35 years, with
singleton pregnancy without illicit drug use and HIV infec-
tion, free from chronic diseases such as diabetes or hyperten-
sion, and residing in Krakow for at least 1 year prior to the
pregnancy. The infants were followed up to the 9th year of
life. Each year, mothers were asked to provide information on
infants’ health and household characteristics by trained inter-
viewers, who carried out detailed, face-to-face standardized
interviews. The Test of Nonverbal Intelligence, Third Edition
(TONI-3) was administered to mothers. We have included this
instrument to adjust to the maternal contribution to the child’s
cognitive development.
Vaccination data
The data on infants’ vaccination history (date of vaccination
and type of vaccine) were extracted from the physician’s
records. Neonatal thimerosal exposure status was based on
hepatitis B vaccination in the first 29 days of life (first dose). A
further level of TCVexposure took into consideration hepatitis
B as well as diphtheria-tetanus-pertussis (DTPw or DTPa)
vaccines up to the 6th month of life.
Biological samples and analysis
Heavy metal (mercury, lead) concentrations were examined in
cord blood (at delivery) and capillary blood (5-year-old chil-
dren). Whole blood lead concentrations were determined
using inductively coupled plasmamass spectrometry CLIA’88
method “Blood lead cadmium mercury ICPMS_ITB001A.”
This multielement analytical technique is based on quadruple
ICP-MS technology [3]. Mercury levels were measured at the
Center for Disease Control by Zeeman graphite furnace atom-
ic absorption spectrometry, using a phosphate/Triton X-100/
nitric acid matrix modifier. Cold vapor atomic spectrometry
following chemical reduction of mercury compounds was
used to measure total mercury in whole blood. More details
on blood sample collection and analysis were presented in the
earlier publications [9, 10].
Infant neurodevelopment testing
The Fagan Test of Infant Intelligence (FTII) was conducted at
the 6th month of life. The Bayley Scales of Infant Develop-
ment, Second Edition (BSID-II) was administered at the 12th,
24th, and 36thmonth of life. TheMental Scale of BSID_II test
includes items that assess memory, habituation, problem solv-
ing, early number concepts, generalization, classification, vo-
calization, language, and social skills [2]. Test scores are
adjusted to the child’s age to obtain the Mental Development
Index (MDI). Test results are in one of four categories: (1)
accelerated performance (score >115), (2) within normal
limits (score 85 to 114), (3) mildly delayed performance (score
70 to 84), and (4) significantly delayed (score <69). Results
<85 were considered as poorer cognitive development.
The test of Raven’s Colored Progressive Matrices (Raven)
was administered twice, at the 5th and 8th year of life. The
outcomes of the test were measured in terms of centiles.
Because the results of this test were generally high, the cut
point of poor result category was 75th percentile, which
means middle intelligence outcomes.
The Wechsler Intelligence Scale for Children-Revised
(WISC-R) was administered at the 6th, 7th, and 9th year of
life and generated verbal, non-verbal, and total IQ for the
evaluated children. The outcome’s range is from 40 to 160.
The category with IQ <110 was considered as the poorer
outcomes.
All neurodevelopment tests were conducted at the Depart-
ment of Epidemiology and Preventive Medicine by carefully
trained examiners who were unaware of the child’s exposure.
The Bayley Scales as well as the Raven test have well-defined
criteria and were considered as fully consent between the
different examiners. In order to provide a fully comparable
assessment of the WISC-R test, one psychologist rated per-
formed answers for all the children.
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Confounders
Data on possible confounders such as maternal age (continu-
ous variable) and education (university vs. non-university);
maternal non-verbal intelligence (result of the TONI-3 as a
continuous variable); older siblings (yes or no); exposure to
passive tobacco smoking during pregnancy (yes or no); child’s
gender, gestational age (≥37 vs. <37 weeks), birth weight
(continuous variable, unit 100 g), Apgar score, blood mercury
and lead level (cord and at the age of 5), breastfeeding (chil-
dren breastfed for at least 6 months), and exposure to
ethylmercury in later life (from the 29th day to the 6th month)
were collected and included in the analysis.
Statistical analysis
In the descriptive analysis, differences in the distribution of
women and newborns’ parameters grouped by thimerosal
vaccination status were tested using χ2 (for nominal variables)
and the Mann-Whitney and Kruskal-Wallis tests (for continu-
ous variables).
The comparison of the test outcomes according to the
exposure to the type of vaccine (TCVs vs. non-TCV-
vaccinated group) was studied using multivariate linear
models. The logistic models were used to assess risk of poorer
developmental outcomes (MDI <85, Raven <75, IQ <110) as
well. All variables from Table 1 showing a probable associa-
tion with thimerosal vaccination status (p<0.1) were included
in statistical multivariable models. Blood lead level at the age
of 5 was used as a confounder in models for 5-year-old and
older children. Additionally, the child’s gender was added to
all models as it is highly associated with developmental tests’
performance.
Statistical analyses were performed using STATA software
version 12.1.
Results
The analyzed population consisted of 318 children: 52.8 %
boys and 47.2 % girls. One child from that group (0.3 %) was
absent during FTII and BSID-II test at the 12th month. In that
group, retention rate during psychological tests in further
years was 97.5 % at 2nd, 94.7 % at 3rd, 78.3 % at 5th,
60.7 % at 6th, 67.9 % at 7th, 55.0 % at 8th, and 64.8 % at
9th with reference to the initial cohort, respectively. Retention
rates were comparable between studied groups.
In the analyzed group, all but one child were vaccinated
against hepatitis B in the neonatal period, 220 (69.2 %) of
them with TCVs. Ninety-eight (30.8 %) children were vacci-
nated with thimerosal-free Engerix B, 162 (50.9 %) with
Euvax B, and 58 (18.2 %) with Hepavax-Gene, the latter
two containing 25 μg thimerosal per dose. Most of the chil-
dren (302, 95.0 %) were vaccinated within 1 day after birth
and an additional nine (totally 97.8 %) within 1 week.
Exposure to TCVs up to the age of 6monthswas connected
with further doses of hepatitis B and DTPw/DTPa vaccines
administered according to the Polish immunization schedule.
The children were vaccinated with DTPw vaccine with thi-
merosal (25 μg/dose) manufactured in Poland and thimerosal-
free vaccines (DTPa), such as Infanrix IPV+Hib, Infanrix
Hexa, Tripacel, and Tetracoq. All the analyzed vaccines (thi-
merosal-containing and thimerosal-free) contained aluminum
compounds as adjuvant.
Between the 29th day and the 6th month of life, 86.2 % of
children were vaccinatedwith TCVs. The children immunized
with ethylmercury-containing vaccines in the neonatal period
were more frequently vaccinated with ethylmercury later in
their life compared to those not immunized with TCVs (92.3
vs. 72.4 %, p<0.001). Figure 1 presents the distribution of
exposure to TCVs in the period of the first 6 months of life.
Neonatal exposure to TCVs was derived from hepatitis B
vaccine only which was mainly administrated in the first 24 h
after delivery. It was dependent on the decision of theMinistry
of Health, who decided about the kind of vaccine (cheaper or
more expensive) secured for all children in Poland at the same
period of time. In the group of children examined, those born
in 2001 were vaccinated almost only (89.2 %) with
thimerosal-free vaccines, while those born in 2002–2004 with
TCV (96.8 %) in the neonatal period. This vaccination was
independent of parents’ decision. No significant differences
were found for maternal characteristics such as age, education,
and the TONI-3 scores, between the children exposed and
non-exposed to TCVs in the neonatal period. Passive tobacco
smoking during pregnancy was less common among the
mothers of children from the neonatal TCV group (32.7 vs.
48.0 %, p=0.010). On the other hand, further exposure to
TCVs depended partly on the Ministry of Health decision and
partly on family socioeconomic status that can be seen in
significant differences in maternal and paternal education
levels (Table 1). Also, prematurely born children were less
often vaccinated with TCV.
As for child characteristics, only the lead level in cord
blood was significantly lower in the TCV-exposed group than
in the non-exposed one (1.3 vs. 1.7 μg/dL, p<0.001, for
exposure in the neonatal period and 1.3, 1.4, and 1.7 μg/dL
in the 6-month period) (Table 1).
The outcomes of cognitive development
The results of psychological tests verifying children’s cogni-
tive development were mostly on the same level in groups
exposed and non-exposed to TCVs in both neonatal and 6-
month periods, which were presented in Fig. 2a, b. The
significant differences among exposures in the neonatal period
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were observed in the Fagan (58.5 vs 61.2, p=0.002), the MDI
at the 36thmonth (101.6 vs 104.6, p=0.024), and theWISC-R
at the 9th year according to verbal (69.0 vs 73.0, p=0.003) and
total (125.4 vs 130.4, p=0.005) IQ levels, which were higher
in the TCV-exposed groups. After standardization to child’s
gender, mother ’s higher education, prenatal ETS,
breastfeeding up to 6 months, Hg in cord blood, as well as
the exposure to thimerosal from the 29th day up to the 6th
month, only the MDI of the BSID-II (β=4.10, p=0.016) and
the WISC-R (β=3.96, p=0.040 for verbal IQ, and β=4.73,
p=0.049 for overall IQ) differences remained significant
(Table 2). All developmental tests performed from the 5th to
9th year were additionally standardized to bloodmercury level
which was measured when children were 5 years old. Signif-
icant differences in the MDI levels observed at the age of
12 months connected with thimerosal exposure during
6 months after birth were observed only in univariate analysis
Table 1 Characteristics of the study subjects by neonatal and 6-month ethylmercury exposure
Neonatal exposure to TCV Thimerosal exposure up to 6 months
Non-exposed
(N=98)
Exposed
(N=220)
p No exposure
(N=27)
From 25 to
50 μg (N=117)
Above 50 μg
(N=174)
p
N % N % N % N % N %
Maternal education level 0.536
Elementary/ vocational school 11 11.2 17 7.7 1 3.7 4 3.4 23 13.2 0.009
High school 39 39.8 85 38.6 10 37.0 41 35.0 73 42.0
University 48 49.0 118 53.6 16 59.3 72 61.5 78 44.8
Maternal marital status 90 91.8 209 95.0 0.272 26 96.3 111 94.9 162 93.1 0.719
Poor economical status 4 4.1 20 9.1 0.118 0 – 7 6.0 17 9.8 0.146
Paternal education 0.985
Elementary/ vocational school 12 13.0 27 13.4 2 7.7 7 6.7 30 18.4 0.006
High school 28 30.4 63 31.2 5 19.2 30 28.6 56 34.4
University 52 56.5 112 55.4 19 73.1 68 64.8 77 47.2
Passive tobacco smoking during pregnancy 47 48.0 72 32.7 0.010 14 51.9 31 26.5 74 42.5 0.006
Boys 49 50.0 119 54.1 0.500 16 59.3 65 55.6 87 50.0 0.508
Gestational age <37 weeks 4 4.1 7 3.2 0.743 3 11.1 8 6.8 0 – <0.001
Older siblings 40 40.8 78 35.5 0.361 9 33.3 42 35.9 67 38.5 0.825
Breastfeeding up to 6 months 71 72.4 154 70.0 0.658 19 70.4 86 73.5 120 69.0 0.705
Passive tobacco smoking during 5 years 16 19.5 54 28.7 0.112 3 12.5 20 21.1 47 31.1 0.062
Mean SD Mean SD Mean SD Mean SD Mean SD
Mother’s age at the 2nd trimester 27.5 3.84 27.6 3.52 0.907 28.3 3.94 28.0 3.31 27.1 3.73 0.073
Maternal non-verbal intelligence (TONI-3) 105.7 19.06 110.3 17.04 0.082 108.3 20.39 110.0 17.77 108.6 17.36 0.834
Birth weight [g] 3391.5 531.52 3412.4 469.47 0.726 3206.3 637.80 3391.0 518.85 3447.0 433.44 0.053
Head circumference at birth [cm] 33.9 1.65 33.8 1.44 0.962 33.3 1.88 33.9 1.52 33.9 1.42 0.404
Cord blood mercury level [μg/L] 0.9 0.44 1.0 0.68 0.300 1.0 0.57 1.1 0.76 1.0 0.56 0.570
Cord blood lead level [μg/dL] 1.7 0.91 1.3 0.49 <0.001 1.7 0.65 1.3 0.65 1.4 0.67 0.001
Blood mercury level [μg/L] 2.1 0.67 2.2 0.74 0.056 2.0 0.59 2.1 0.81 2.2 0.68 0.409
Blood lead level [μg/dL] 0.6 0.26 0.5 0.32 0.224 0.6 0.33 0.6 0.31 0.5 0.30 0.495
SD standard deviation, p significance level
Fig. 1 Distribution of ethylmercury doses in the 6-month period
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Fig. 2 Average development test scores in the ethylmercury-exposed and non-exposed groups in the a) neonatal b) 6 month period. *p<0.05. MDI
Mental Development Index of BSID-II, WISC-R V WISC-R verbal scale, WISC-R P WISC-R performance scale
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(93.9, 102.8, and 101.4, p=0.003). After standardization to
the above mentioned variables, they lost their significance
(β=−0.09, p=0.825) (Table 2).
Risk of poorer outcomes in cognitive development
According to assumed criteria, poorer outcomes in MDI re-
sults were present in 7.3 % of children at the 1st year, 9.0 % at
the 2nd year, and 4.3% at the 3rd year of life. Poorer outcomes
of the Raven test were present in 20.9 % of children tested at
the 5th year of life and 16.6 % of those tested at the 8th year of
life.
WISC-R IQ results less than 110 were observed for 14.5–
22.3 % of 6-year-old, 8.3–17.1 % of 7-year-old, and 3.9–
14.1 % of 9-year-old children. No significant differences were
observed in the proportion of children with poorer cognitive
test results caused by neonatal TCVexposure in the case of all
studied tests, but Raven in the 8th year. Similarly, we did not
observe any differences in the proportion of children getting
poorer results according to exposure to TCVs in the 6-month
period. Multivariable analysis of risk of obtained poorer cog-
nitive results from the 1st to 9th year of life did not show that
TCVexposure may affect the studied results (Table 3).
Discussion
We did not find any negative correlation between neonatal and
early infancy TCVexposure and mental development in chil-
dren up to 9 years of age. Our results are consistent with the
observations of other authors who did not confirm the influ-
ence of TCVs on mental development [1, 8, 21]. On the other
hand, some other reports indicated both beneficial and adverse
effects of TCVs on children’s development [14]. This fact
may result from the methodological differences of the epide-
miological studies and the time elapsed between the exposure
and the development assessment.
The advantage of our study is the long-term, 9-year survey
of the cohort with methodological assessment of children’s
development with an average 1-year interval between the
administered tests. Differently from the other authors, we
obtained the outcomes of children’s mental development after
shorter and longer periods of time following early TCVexpo-
sure. Hence, we had the possibility to adjust the crude results
to many important confounders that could influence develop-
ment during the first years of life. The strength of the study is
the consistency of the lack of association between early TCV
exposure and mental development in each stage of life up to
Table 2 The association between ethylmercury exposure and developmental test scores up to 9 years of age
Test Age Neonatal exposurea 6-month exposureb
Beta p 95 % CI Beta p 95 % CI
FTII 6th month 1.38 0.248 −0.97–3.72 0.14 0.632 −0.43–0.70
MDI of BSID-II 12th month of life 2.09 0.220 −1.26–5.44 −0.09 0.825 −0.90–0.71
MDI of BSID-II 24th month of life −2.00 0.337 −6.08–2.09 −0.48 0.343 −1.46–0.51
MDI of BSID-II 36th month of life 4.10 0.016 0.76–7.43 0.78 0.060 −0.31–1.58
Raven (centiles) 5th year of life −0.29 0.937 −7.50–6.92 −0.77 0.619 −2.45–0.92
WISC-R 6th year of life
Verbal IQc 2.32 0.399 −3.12–7.76 −0.62 0.337 −2.01–0.77
Non-verbal IQc 3.31 0.279 −2.72–9.35 −0.70 0.374 −2.24–0.85
IQc 2.98 0.256 −2.19–8.15 −0.73 0.273 −2.05–0.59
WISC-R 7th year of life
Verbal IQc −1.66 0.513 −6.65–3.34 −1.12 0.265 −1.88–0.52
Non-verbal IQc −0.72 0.802 −6.41–4.96 0.43 0.534 −0.94–1.80
IQc −1.33 0.560 −5.87–3.19 −0.14 0.805 −1.23–0.96
Raven (centiles) 8th year of life −3.40 0.325 −10.22-3.42 −0.35 0.691 −2.09–1.39
WISC-R 9th year of life
Verbal IQc 3.96 0.040 0.18–7.75 0.02 0.963 −0.99–1.04
Non-verbal IQc 3.20 0.214 −1.87–8.27 −0.71 0.285 −2.02–0.60
IQc 4.73 0.049 0.03–9.44 −0.40 0.527 −1.64–0.84
a Standardized to child’s gender, mother’s higher education, prenatal ETS, breastfeeding up to 6 months, Hg in cord blood, as well as exposure to
thimerosal from the 29th day up to the 6th month
b Standardized to child’s gender, mother’s higher education, prenatal ETS, breastfeeding up to 6 months, and dHg in cord blood; exposure to
ethylmercury as continuous variable formulated as number of TCV doses
c Additionally standardized to blood Hg level in 5-year-old children
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the 9th year of life after standardization to many important
confounders. This consistency of outcomes during so many
years of life gave us strong evidence that early TCVexposure
has no harmful influence on later mental development.
The cohort in our study derived from the general popula-
tion but was different from the other population studies. In our
study, the breastfeeding rate at the 6th month was significantly
higher compared to that of infants from the other cohorts [12].
On the other hand, there are studies related to thimerosal
exposure and neurodevelopment, conducted in a cohort of
exclusively breastfed infants [15]. High breastfeeding rate
could be one of the reasons that there was no negative influ-
ence of early TCV vaccinations on mental development out-
comes. This cannot be attributed solely to the protective
role of breastfeeding because the development depends
on multiple conditions that can eliminate the potential
harmful effect of TCV exposure [19]. For example, in
our cohort, girls had higher scores of mental develop-
ment after TCV exposure compared to boys (not statis-
tically significant). This fact could be derived from the
protective effect of estrogen in girls and the negative
influence of testosterone in boys [5].
The limitation of this analysis is the study cohort which
may not be sufficiently representative of the general
population. The main purpose of the Krakow Cohort Study
was to assess whether the exposure of pregnant women to air
pollutants affects future development of their children. To
avoid biases from the other harmful factors, the enrollment
covered only those pregnant women who were free from
selected chronic diseases, smoking, and occupational expo-
sure to chemicals. That made our cohort somewhat healthier
than the entire population.
At first, our study was concentrated on TCV vaccinations
in newborns, who greatly differ in their birth weight and
maturity. These have an influence on ethylmercury
toxicokinetics and toxicodynamics [18]. The newborns re-
ceived different doses of ethylmercury per kilogram of body
mass dependent on birth weight. Since immaturity is not a
contraindication to hepatitis B vaccination, nearly all the
newborns were vaccinated during the first days of life, inde-
pendent of their birth weight and gestational age. In our
cohort, the representation of newborns born at gestational
age <37 weeks was relatively smaller compared to the general
population. This special population of immature newborns
with low and extremely low birth weight requires further
studies.
The main strength of our study was a possibility to deter-
mine whether there is an association between early TCV
Table 3 The risk of delay in cognitive development according to ethylmercury exposure
Test Age Neonatal exposurea 6-month exposureb
OR p 95 % CI OR p 95 % CI
MDI of BSID-II 12th month of life 0.58 0.238 0.24–1.42 0.93 0.597 0.71–1.22
MDI of BSID-II 24th month of life 1.04 0.928 0.44–1.47 0.98 0.873 0.76–1.26
MDI of BSID-II 36th month of life 0.56 0.341 0.17–1.84 0.80 0.242 0.55–1.16
Raven (centiles) 5th year of life 0.93 0.835 0.47–1.84 0.99 0.923 0.82–1.20
WISC-R 6th year of life
Verbal IQc 0.75 0.457 0.35–1.59 1.15 0.216 0.92–1.44
Non-verbal IQc 0.91 0.825 0.40–2.06 0.97 0.968 0.79–1.28
IQc 1.16 0.736 0.47–2.90 0.97 0.812 0.75–1.26
WISC-R 7th year of life
Verbal IQc 0.79 0.576 0.35–1.78 1.04 0.717 0.83–1.32
Non-verbal IQc 0.71 0.482 0.28–1.83 0.74 0.049 0.55–1.00
IQc 0.52 0.222 0.18–1.49 0.81 0.231 0.57–1.14
Raven (centiles)c 8th year of life 2.69 0.224 0.55–13.19 1.07 0.609 0.83–1.37
WISC-R 9th year of life
Verbal IQc 0.45 0.076 0.19–1.09 1.00 0.984 0.77–1.30
Non-verbal IQc 1.04 0.952 0.28–3.81 0.84 0.378 0.58–1.23
IQc 0.42 0.248 0.09–1.84 0.76 0.247 0.47–1.21
a Standardized to the child’s gender, mother’s higher education, prenatal ETS, breastfeeding up to 6 months, as well as exposure to thimerosal from the
29th day up to the 6th month
b Standardized to the child’s gender, mother’s higher education, prenatal ETS, and breastfeeding up to 6 months; exposure to ethylmercury as continuous
variable formulated as number of TCV doses
c Additionally standardized to blood Hg level in 5-year-old children
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exposure and mental delays of milder intensity. Most of the
previous epidemiological studies were addressed to the links
between ethylmercury exposure and more serious potential
side effects in children. We revealed, using very precise men-
tal development tests, that there is not even a subclinical
harmful effect of early TCV vaccinations on mental develop-
ment. The other strong point of our study was the active
follow-up of pregnant mothers and their children. It gave us
a possibility to control many important confounders potential-
ly affecting children’s development. An adjustment to mercu-
ry exposure—prenatal (cord blood) and blood level at the 5th
year of life—was the most important for that analysis. It is a
very precise equivalent of mercury derived from the other
sources, for example methylmercury from fish consumption
that demonstrated harmful consequences on children’s
neurodevelopment [13, 17]. Additionally, our analysis related
to the neonatal period and included adjustment to post-
neonatal TCVexposure up to the 6th month.
Conclusions
We found no negative association between neonatal and early
infancy TCVexposure and mental development in children up
to 9th year of age. The results of our study should not be
treated as a supportive argument for continuation of early
TCV exposure if it is economically unnecessary. They may
be interpreted as further evidence on the vaccines’ safety even
if they still contain thimerosal.
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